PharmaTalkRadio

In the fourth episode of our series highlighting rare diseases, Conference Forum reporter Danny McCarthy sits down with Neena Nizar, EdD, Founder and Executive Director of the Jansen's Foundation, to discuss Jansen's Metaphyseal Chondrodysplasia.  Jansen type metaphyseal chondrodysplasia is an extremely rare progressive disorder in which portions of the bones of the arms and legs develop abnormall...

In this podcast, first presented at the 9th annual DPharm: Disruptive Innovations conference, Cellarity's Milind Kamkolkar presents on the collective struggle to evolve a drug development organization's data and analytics culture and capabilities. Including: The theory of going digital in drug developmentIdentifying hype from realityWhat is the program we are trying to solve? Take a big, complex o...

In this podcast, first presented at the 9th annual DPharm: Disruptive Innovations conference, Genentech's Aaron Mann discusses the use of historical data to transform clinical trials and how to rethink clinical development. Speaker: Aaron Mann, Global Program Lead, Industry Collaborations Data Sharing Initiatives, Genentech, a member of the Roche Group The 10th annual DPharm: Disruptive Innovation...

In this podcast, first presented at the 9th annual DPharm: Disruptive Innovations conference, Johnson & Johnson's Dr Martine Lewi discusses the evolution of their use of Real-World Data in their clinical programs. Including: What is the state of the art in real-world data and how is patient data being used today? Innovation initiatives at J&JAccelerating the drug development cycle Speaker:...

In this podcast, first presented at the 9th annual DPharm: Disruptive Innovations conference, Sanofi's Laura Kling discusses developing a digital endpoint for Parkinson's Disease using wearables.  Speaker: Laura Kling, Director, Digital Innovation, Sanofi The 10th annual DPharm: Disruptive Innovations event is scheduled to take place on September 22-23, 2020. Learn more here.

This podcast presents a session on planning for and addressing missing data form the 2019 Mobile in Clinical Trials conference.  When a protocol dictates a set period of time for data collection, what happens when there's a gap in the data due to technical glitches or human error? What are the regulatory and operational implications? Discussion points include: How to prepare for missing dataHow do...

In this podcast, first presented at the 9th annual DPharm: Disruptive Innovations conference, Merck's Mark Travers presents a cornerstone discussion on Balancing Innovation with Solid Common Sense to Deliver Innovative Medicines. Merck is walking the walk in disrupting how to restore best practices for people, products, and productivity. With a clear vision on output, their remarkable team mapped...

This podcast presents a panel discussion from the 2019 Mobile in Clinical Trials conference on what we are striving for and measurements of success in virtual trials. Discussion points include: How is it getting our of pilotville? What is the barrier to adoption? Factors that impact success: Risks and Patient Preferences Moderator: Adama Ibrahim, EMBA, Associate Director, Performance Operational C...

This podcast presents a session from the 2019 Mobile in Clinical Trials conference on Escaping Pilotville: How to Scale Mobile/Digital Deployment in Clinical Trials. Discussion points include: What KPIs are used to evaluate success/failure of a pilot? What are the barriers to scale, even when a pilot is a success? What are the operational models used by innovation teams to support deployment? Whic...

This podcast presents a session from Merck on Mobilizing Mobile Efforts and Engineering for Scale at the 2019 Mobile in Clinical Trials conference.  Mobile tool/device implementation has been widely accepted, tested, and piloted in clinical research. With the bar set, Merck looks to challenge it and create an ecosystem that continues to set the bar higher with a scalable model. In this session, Ka...

This podcast presents a panel discussion on What a Successful Digital Trial Looks Like from the 2019 Mobile in Clinical Trials conference. Including: What is a digital trial? Is a common definition needed in order to scale for success? What does success look like? Fully remote, data sharing, device/tool implementation? How do we measure success? And when? What about accessibility?patient/investiga...

In the third episode of our series highlighting rare diseases, Conference Forum reporter Danny McCarthy sits down with Fernando Albertorio, PhD, to discuss Hermansky-Pudlak Syndrome.  Dr Albertorio is co-founder of Sunu, Inc, which creates wearable, IoT and mobile technology that empowers independence for people who a blind and visually impaired. Dr Albertorio is also an advocate for increasing aw...

The COVID-19 pandemic has meant that, more and more, clinical trials are being disrupted or interrupted completely. Without the continuous momentum and contact, trials will lose patients as gaps in studies lengthen.  To combat that, Be the Partner designed “Bridge,” a new solution on their Patient Portal specifically for continuing secure, ongoing connectivity with trial patients during any tempor...

PharmaTalk Radio's Valerie Bowling welcomes guest, Kent Thoelke, EVP and CSO at PRA Health Sciences on his experience in rapidly setting up both therapeutic and vaccine focused programs for COVID-19. More specifically, they discuss lessons learned, what the new normal will look like for clinical trials and serving the needs of thousands of people who are currently in clinical trials.  Guest Bio: K...

In the second episode of a three-part series dedicated to highlighting rare disease, Conference Forum reporter Danny McCarthy sits down with C Frank Bennett, PhD, of Ionis Pharmaceuticals, to discuss Spinal Muscular Atrophy. Dr Bennett is Executive Vice President and Chief Scientific Officer at Ionis Pharmaceuticals, and one of the founding members of the company. He is responsible for continuing...

In this three-part series dedicated to the physician's perspective on living with a rare disease, Conference Forum reporter Danny McCarthy sits down with Tracy Frech, MD, to discuss Systemic Sclerosis. Tracy Frech, MD, is a rheumatologist at the University of Utah. At the university, she is the Director of the Systemic Sclerosis (SSc, scleroderma) Clinic at the University of Utah Hospital and the...

In this podcast moderated by Dr Michael Kalos, Janssen Oncology, you will hear a panel discussion from the 2019 IO Combinations 360° conference. Topic points include: What are the new opportunities in cell therapy for combinations? What the challenges are going to be with the microenvironment? What is being done to engineer cell therapy? How do you develop CARs and TCRs that deliver payloads? How...

Anti-PD-1 therapy has transformed cancer care but most patients do not respond. It is increasingly clear that there will be no single biomarker of response to a PD-1, and that a multi-omic approach will be required. In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Danny Wells, Parker Institute for Cancer Immunotherapy will address: Orthogonality and correlation...

In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Darren Hodgson, AstraZeneca presented updates on PARP inhibition. Topics include: Strategies to target homologous recombination repair deficiencyMonotherapy indications and current development landscapeScientific hypotheses being explored in olaparib combinations To learn more about the upcoming IO Combinations 3...

First recorded at the 4th annual IO Combinations 360° conference, this talk provided by Dr Kenneth Hance, GSK addresses agonistic strategies, T and NK cell redirection and the use of genetic/phenotypic assocations to identify novel target space in IO. To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com

In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Laureen Ojalvo, EMD Serono provides an overview of the moleculte Bintrafusp alfa/M7824. This molecule is an innovative, first-in-class bifunctional fusion protein composed of an anti-PD-L1 mAb fused with 2 extracellular domains of TGF-βRII (a TGF-β “trap”). The mechanism of action, pre-clinical and phase 1 studie...

In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Willem Overwijk, Nektar Therapeutics discusses Bempegaldesleukin (NKTR-214): harnessing the IL-2 pathway in combination immunotherapies. Topics include: Bempegaldesleukin: Structure and function of an engineered IL-2 cytokine prodrug providing sustained IL-2Rβγ-biased signalingPreclinical PK, PD, MOA and combinat...

First recorded at the fourth annual IO Combinations 360° conference, this panel moderated by Dr Daniel Chen, IGM Biosciences discusses advancing bispecifics for combination immunotherapy. This discussion covers the following topics: What are the types of bispecifics and what are the limitations? What are the toxicity related side effects? What are teh next steps/levels for bispecifics? What does t...

In this podcast, you will hear a panel discussion from the 2019 IO Combinations 360° conference regarding how AI, machine learning and big data are used to inform combinations. Moderated by Matthew Albert, MD, PhD, Insitro Panelists: Edward Bowen, GSK Ryan Fukushima, Tempus Renée Deehan-Kenney, PhD, QuartzBio, part of Precision for Medicine To learn more about the 2020 IO Combinations 360° confere...

In this podcast, you will hear a panel discussion from the 2019 Clinical Research as a Care Option (CRAACO) conference with patients and advocates on weighing your care options and considering participation in a clinical trial. Some points include, Strategies and ideas to reduce the burden to patientsUnderstanding of clinical care with their physician? Communication, consent and data sharing Moder...